Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A | P35498 | 16/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 16/20 | 0.36 |
| ▸ | SCN8A | Q9UQD0 | 16/20 | 0.36 |
| ▸ | SCN1B | Q07699 | 2/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19634337 | 0.88 | SCN1A (0.33) | SCN1ASCN5ASCN8ASCN1BSCN9A | |
| SCHEMBL20256344 | 0.79 | SCN8A (0.46) | SCN1ASCN5ASCN8ASCN1B | |
| SCHEMBL19634137 | 0.77 | SCN1A (0.35) | SCN1ASCN5ASCN8ASCN1BSCN9A | |
| SCHEMBL20256320 | 0.76 | SCN8A (0.48) | SCN1ASCN5ASCN8ASCN1BNR1I2 | |
| SCHEMBL19634111 | 0.75 | SCN1A (0.36) | SCN1ASCN5ASCN8ASCN1BSCN9A | |
| SCHEMBL19613278 | 0.70 | SCN8A (0.65) | SCN1ASCN5ASCN8ASCN1BSCN9A | |
| SCHEMBL19634164 | 0.70 | SCN1A (0.35) | SCN1ASCN5ASCN8ASCN1BSCN9A | |
| SCHEMBL20256587 | 0.69 | SCN8A (0.64) | SCN1ASCN5ASCN8ASCN1BSCN9A | |
| SCHEMBL20256239 | 0.68 | SCN1A (0.47) | SCN1ASCN5ASCN8ASCN1BNR1I2 | |
| SCHEMBL19634085 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017201468-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2017-11-23 | — | — | WO | disclosed |